Additionally, they prove that use of the c-Rel inhibitor pentoxifylline (PTXF) in combination with anti-PD-1 antibodies increases the number of tumor infiltrating T cells and potentiates the beneficial effects of PD-1 blockade in a melanoma mouse model [19]. Here, PDCD1 is linked to neoplasm.